Physician profile
Ronald Perrott
NPI 1629104427
$5,379.47
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $665 · 2021: $889 · 2022: $1,316 · 2023: $1,252 · 2024: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $716.62 | 2019-2024 | |
| Amgen INC. | $637.27 | 2020-2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $520.84 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $421.21 | 2019-2024 | Absorica Ld, Winlevi, Ilumya |
| Leo Pharma INC. | $396.19 | 2019-2024 | Adbry |
| Lilly USA, LLC | $385.05 | 2019-2024 | Taltz, Olumiant |
| Genzyme Corporation | $275.15 | 2019-2023 | |
| Celgene Corporation | $213.55 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $161.89 | 2019-2024 | Targretin, Siliq |
| Arcutis Biotherapeutics, INC. | $143.12 | 2023 | |
| Janssen Biotech, INC. | $126.70 | 2019-2024 | Tremfya |
| Pfizer INC. | $124.40 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $123.43 | 2019-2022 | |
| Galderma Laboratories, L.P. | $103.94 | 2020-2022 | |
| Almirall LLC | $102.67 | 2020-2023 | Seysara |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $97.55 | 2019-2023 | Dupixent |
| Epi Health, LLC | $81.79 | 2019-2022 | |
| Dusa Pharmaceuticals, INC. | $81.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.05 | 2022-2023 | Spevigo |
| Genentech USA, INC. | $75.23 | 2019-2021 | |
| Dermavant Sciences, INC. | $69.89 | 2023 | Vtama |
| Sebela Pharmaceuticals INC. | $55.68 | 2022-2023 | Naftin, Pramosone |
| Kyowa Kirin, INC. | $54.78 | 2021-2023 | Poteligeo |
| Aclaris Therapeutics, INC. | $52.30 | 2019 | |
| Convatec INC. | $45.98 | 2023-2024 | |
| Incyte Corporation | $45.00 | 2022 | |
| Smith+Nephew, INC. | $30.47 | 2023 | Collagenase Santyl |
| Journey Medical Corporation | $29.06 | 2022 | |
| Ucb, INC. | $24.62 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.92 | 2023 | Sotyktu |
| Astrazeneca Pharmaceuticals LP | $20.39 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.18 | 2019 | |
| Merck Sharp & Dohme LLC | $12.77 | 2019 | |
| Dermira, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Perrott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.